Pfizer Inc. (NYSE: PFE) Records a Gain of 42.2% in the Last Six Months

Pfizer Inc. (NYSE: PFE) has gained 42.2% in the past six months. This is because of some of its breakthrough projects, including receiving approval from the Food and Drug Administration (FDA) for its COVID-19 booster.

The company also received approval for vaccines for children between 12 to 15. Moreover, Pfizer received Breakthrough Therapy Designation (“BTD”) to AbbVies lung cancer candidate.

Study shows that unvaccinated people have higher rates of hospitalization

The rate of COVID-19 infections in New York is on the rise; however, medical experts state that though the number has increased more than 7-fold in December, they cannot compare it to the new infections rising among the unvaccinated. 

A recent survey revealed that the vaccine’s effectiveness against severe infection was still high, with 4.59 out of 100,000 fully vaccinated grown-ups hospitalized with COVID during the December 27 week. However, it is essential to note that the number of unvaccinated residents with COVID was 13 times higher. 

South Korea’s health officials will start treating their COVID patients with Pfizer’s antiviral pills as concern over Omicron’s wave continues. The officials stated that the medication would treat more than 1,000 patients daily. 

The officials also emphasized prioritizing patients with low immunity or those older than 65 years. At least 21,000 pills will arrive on Thursday and be distributed to 280 pharmacies and 90 residential treatment centers.

 The study will test the efficacy of the Pfizer vaccine on patients with HIV

A South African study will assess the safety and impact of varying doses of J&J and Pfizer shots as boosters for HIV and the population. The Johannesburg- based Wits Reproductive Health and HIV institute will recruit approximately 300 health workers. 

Nearly a third of them will be HIV positive. The study will also evaluate the safety and immunogenicity of the vaccine.

Pfizer recently announced positive results from a Phase 3 study that described the safety of PREVNAR 20 in 570 adults in the United States. They administered the drug to people 65 years and older at a similar moment as the Pfizer-BioNTech COVID-19 Vaccine, or when they combined, each vaccine was given with a placebo.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.